Skip to main content
Equibles
RCEL logo

RCEL · AVITA Medical, Inc. · Webcasts, Transcripts & Audio

Track RCEL — free

Use RCEL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RCEL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.65 -1.06 (-6.34%) At close · Oct 30 Q2 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on the Company's liquidity position and the Company's current forecast of operating results and cash flows, management determined there is substantial doubt about the Company's ability to continue as a going concern over the next twelve months following the date of issuance of these Consolidated Financial Statements due to the Company's debt repayment obligations, recurring losses, and historical negative cash flows.”
View the 10-Q filed Aug 6, 2026
Market Cap
$484.01M
Shares
30.93M
Volume · Oct 30 597.05K Avg daily vol (3M) 484.46K

AVITA Medical, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for AVITA Medical, Inc. (RCEL), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q2
2026-08-06
AVITA Medical, Inc. (RCEL) Q2 2026 Earnings Call Transcript
Confident tone Revenue growth and scale Gross margin and operating leverage 2026 guidance raise
Revenue
$21.70M
▲ 17.8% YoY
Diluted EPS
$-0.25
Gross margin
81.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-14
AVITA Medical, Inc. (RCEL) Q1 2026 Earnings Call Transcript
Positive tone RECELL reimbursement recovery and demand normalization Cohealyx commercial early adoption and clinical data BARDA burn emergency preparedness contract
Revenue
$19.25M
▲ 4% YoY
Diluted EPS
$-0.35
Gross margin
81.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-12
AVITA Medical, Inc. (RCEL) Q4 2025 Earnings Call Transcript
Positive tone Product platform: ReCell, CoHiliX, PermeDerm Utilization and account adoption CoHiliX VAC committee reviews
Revenue
$17.62M*
▼ 4.3% YoY
Gross margin
81.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
AVITA Medical, Inc. (RCEL) Q3 2025 Earnings Call Transcript
Balanced tone RECELL product and adoption Reimbursement clarity and MAC rates Cohealyx and PermeaDerm portfolio expansion
Revenue
$17.06M
▼ 12.7% YoY
Diluted EPS
$-0.46
Gross margin
81.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
AVITA Medical, Inc. (RCEL) Q2 2025 Earnings Call Transcript
Positive tone Product portfolio expansion OrbiMed credit facility amendment Real-world evidence / clinical data
Revenue
$18.42M
▲ 21.2% YoY
Diluted EPS
$-0.38
Gross margin
81.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
AVITA Medical, Inc. (RCEL) Q1 2025 Earnings Call Transcript
Confident tone Cohealyx Launch RECELL GO mini Launch Vitiligo Pause / Risk
Revenue
$18.51M
▲ 66.7% YoY
Diluted EPS
$-0.53
Gross margin
84.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-07
AVITA Medical, Inc. (RCEL) Q4 2024 Earnings Call Transcript
Positive tone Cohealyx dermal matrix Revenue guidance and Q1 outlook Clinical evidence and study enrollment
Revenue
$18.41M*
▲ 29.7% YoY
Gross margin
87.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
AVITA Medical, Inc. (RCEL) Q3 2024 Earnings Call Transcript
Confident tone RECELL GO platform conversion Cohealyx dermal matrix Comprehensive treatment solution / ASP expansion
Revenue
$19.55M
▲ 43.2% YoY
Diluted EPS
$-0.62
Gross margin
83.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
AVITA Medical, Inc. (RCEL) Q2 2024 Earnings Call Transcript
Positive tone RECELL GO launch and capabilities PermeaDerm adoption VAC approval process and new accounts
Revenue
$15.20M
▲ 29.3% YoY
Diluted EPS
$-0.60
Gross margin
86.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-11
AVITA Medical, Inc. (RCEL) Q1 2024 Earnings Call Transcript
Cautious tone RECELL GO FDA review Wound care portfolio expansion Full-thickness skin defects launch
Revenue
$11.10M
▲ 5.3% YoY
Diluted EPS
$-0.73
Gross margin
86.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-10
AVITA Medical, Inc. (RCEL) Q4 2023 Earnings Call Transcript
Confident tone RECELL GO PMA supplement and launch Commercial revenue growth Sales force expansion and new accounts
Revenue
$14.20M*
▲ 50.1% YoY
Gross margin
87.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
AVITA Medical, Inc. (RCEL) Q3 2023 Earnings Call Transcript
Revenue
$13.64M
▲ 50.1% YoY
Diluted EPS
$-0.34
▼ 254.5% YoY
Gross margin
84.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
AVITA Medical, Inc. (RCEL) Q2 2023 Earnings Call Transcript
Revenue
$11.75M
▲ 41% YoY
Diluted EPS
$-0.41
▼ 264% YoY
Gross margin
81.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-12
AVITA Medical, Inc. (RCEL) Q1 2023 Earnings Call Transcript
Revenue
$10.55M
▲ 39.9% YoY
Diluted EPS
$-0.37
▼ 197.4% YoY
Gross margin
84.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Date not confirmed
AVITA Medical, Inc. (RCEL) Q4 2022 Earnings Call Transcript
Revenue
$9.46M*
▼ 8.2% YoY
Gross margin
85.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
AVITA Medical, Inc. (RCEL) Q3 2022 Earnings Call Transcript
Revenue
$9.09M
▲ 3.7% YoY
Diluted EPS
$0.22
▼ 15.4% YoY
Gross margin
83.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-12
AVITA Medical, Inc. (RCEL) Q2 2022 Earnings Call Transcript
Revenue
$8.34M
▲ 63.3% YoY
Diluted EPS
$0.25
Gross margin
83.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-17
AVITA Medical, Inc. (RCEL) Q1 2022 Earnings Call Transcript
Revenue
$7.54M
▲ 49% YoY
Diluted EPS
$0.38
▼ 20.8% YoY
Gross margin
76.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-11
AVITA Medical, Inc. (RCEL) Q4 2021 Earnings Call Transcript
Revenue
$10.30M
▲ 165.8% YoY
Diluted EPS
$0.19
Gross margin
80.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-12
AVITA Medical, Inc. (RCEL) Q3 2021 Earnings Call Transcript
Revenue
$8.77M
▲ 126.1% YoY
Diluted EPS
$0.26
Gross margin
75.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-27
AVITA Medical, Inc. (RCEL) Q2 2021 Earnings Call Transcript
Revenue
$5.10M
▲ 56.6% YoY
Diluted EPS
$-0.26
Gross margin
83.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-06-17
AVITA Medical, Inc. (RCEL) Q1 2021 Earnings Call Transcript
Revenue
$5.06M
▲ 55.7% YoY
Diluted EPS
$0.48
Gross margin
81.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-12
AVITA Medical, Inc. (RCEL) Q4 2020 Earnings Call
Revenue
$3.88M
Diluted EPS
$-0.60
Gross margin
77.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–23 of 23 webcasts
Key facts CIK 1762303 CUSIP 05380C102 13F (30d) 11 filings 11 filers Visit website